Hypertension in pregnancy and risk of coronary heart disease and stroke: a prospective study in a large UK cohort

Dexter Canoy\textsuperscript{a,1}, Benjamin J. Cairns\textsuperscript{a}, Angela Balkwill\textsuperscript{a}, F. Lucy Wright\textsuperscript{a}, Asma Khalil\textsuperscript{b}, Valerie Beral\textsuperscript{a,1}, Jane Green\textsuperscript{a,1}, and Gillian Reeves\textsuperscript{a,1} for the \textit{Million Women Study Collaborators}

\textsuperscript{a}Cancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Richard Doll Bldg., Roosevelt Drive, Oxford OX3 7LF, UK;
dexter.canoy@ceu.ox.ac.uk
ben.cairns@ceu.ox.ac.uk
angela.balkwill@ceu.ox.ac.uk
lucy.wright@ceu.ox.ac.uk
pa.valerie.beral@ceu.ox.ac.uk
jane.green@ceu.ox.ac.uk
gill.reeves@ceu.ox.ac.uk

\textsuperscript{b}Fetal Medicine Unit, Department of Obstetrics and Gynaecology, St. George's Medical School, University of London, London, UK; akhalil@sgul.ac.uk

\textsuperscript{1}This author is responsible for all aspects of the reliability and freedom from bias of the data presented and their discussed interpretation.

Correspondence to:
Dr Dexter Canoy
Cancer Epidemiology Unit
Nuffield Department of Population Health, University of Oxford
Richard Doll Bldg., Roosevelt Drive, Oxford OX3 7LF, UK
Tel No: +44 1865 289635; Fax No: +44 1865 289610; E-mail: dexter.canoy@ceu.ox.ac.uk

\textbf{Funding source:} This research was supported by Cancer Research UK [Grant C570/A16491], Medical Research Council (Grant MR/K02700X/1), and Oxford University BHF Centre of Research Excellence [British Heart Foundation grant RE/13/1/30181 to B.J.C.].

\textbf{Conflict of interest:} None
Abstract

Background: Many studies investigating long-term vascular disease risk associated with hypertensive pregnancies examined risks in relatively young women among whom vascular disease is uncommon. We examined the prospective relation between a history of hypertension during pregnancy and coronary heart disease (CHD) and stroke in middle-aged UK women.

Methods: In 1996-2001, 1.1 million parous women (mean age=56 years) without vascular disease at baseline reported their history of hypertension during pregnancy and other factors. They were followed for incident CHD and stroke (hospitalisation or death). Adjusted relative risks (RRs) were calculated using Cox regression.

Results: Twenty-six percent (290,008/1.1 million) reported having had a hypertensive pregnancy; 27% (79,163/290,008) of women with hypertensive pregnancy, but only 10% (82,145/815,560) of those without hypertensive pregnancy, reported being treated for hypertension at baseline. Mean follow-up was 11.6 years (mean ages at diagnosis/N of events: CHD=65 years/N=68,161, ischaemic stroke=67 years/N=8365, haemorrhagic stroke=64 years/N=5702). Overall, the RRs (95% confidence interval [CI]) of incident disease in women with hypertensive pregnancy versus those without such history were: CHD=1.29 (1.27–1.31), ischaemic stroke=1.29 (1.23–1.35), and haemorrhagic stroke=1.14 (1.07–1.21). However, among women with hypertensive pregnancy who were not taking hypertension treatment at baseline, their RRs (95% CI) were substantially reduced to: CHD=1.17 (1.14–1.19), ischaemic stroke=1.18 (1.11–1.25), and haemorrhagic stroke=1.09 (1.02–1.18).

Conclusion: Hypertension during pregnancy was associated with increased CHD and stroke incidence in middle age, largely because such women will have had hypertension in their 50s and 60s, which has a substantially greater effect on vascular disease risk than hypertension during pregnancy.

Key words: hypertension; hypertensive pregnancy; women; coronary heart disease; stroke
1. Introduction

Hypertension during pregnancy is an important cause of morbidity and mortality in both the mother and her offspring during the perinatal period [1-3]. Its effect on the mother’s vascular health has been reported to extend for many years after the pregnancy [4-16], but many studies have been in relatively young women among whom vascular disease rates are still relatively low [17, 18]. There is limited information on the impact of hypertension in pregnancy on the vascular health of women in middle age [7, 10, 12, 15, 16] when vascular disease rates are relatively high [17, 18] and unhealthy lifestyles and other factors, such as body mass index, diabetes, dyslipidaemia, and hypertension, become important determinants of coronary heart disease and stroke in the population [19, 20]. Furthermore, separate risks for ischaemic and haemorrhagic strokes remain unclear. We studied the relationship between a history of hypertension during pregnancy and subsequent risks of coronary heart disease and ischaemic and haemorrhagic stroke in a cohort of over a million UK women. We explored these associations in middle-aged women, taking into account their health and lifestyle and other risk factors of vascular disease.
2. Methods

The Million Women Study is a population-based prospective study which recruited 1.3 million UK women aged 50 to 64 years who were invited to routine breast cancer screening programs of the National Health Service (NHS) in England and Scotland from 1996 to 2001. The study design and recruitment have been described in detail previously (www.millionwomenstudy.org) [21]. At recruitment, women filled in a questionnaire which included questions on reproductive and medical history, weight, height, lifestyle, and socio-economic indicators. Around 70% of women invited to attend 66 national breast cancer screening units participated in the study, which is about 1 in 4 of all UK women aged 50 to 64 years at the time of recruitment. Participants gave written consent to take part in the study and the Oxford and Anglia Multi-Centre Research Ethics Committee gave ethical approval to the study. We linked with NHS data sources for hospital admissions and mortality to obtain information on hospitalisations and vital status for the whole cohort [22, 23]. The NHS hospital admissions data for in- and day-patients have been obtained through linkage with the Hospital Episode Statistics [24] for participants in England and the Scottish Morbidity Records [25] for participants in Scotland. Hospital diagnoses and causes of death are reported to the study coded to the World Health Organization’s International Classification of Diseases, Tenth Revision (ICD-10) [26].

At recruitment (baseline for this study), women reported whether or not they ever had high blood pressure during pregnancy, and whether or not they were currently using any medication for selected conditions including hypertension, diabetes, and hypercholesterolaemia. Taking medications particularly for hypertension is a proxy measure for having had a clinically relevant elevation of blood pressure. Women provided information on reproductive factors including age at menarche, parity, and use of hormone replacement therapy. They also reported their smoking habits, alcohol consumption, frequency of strenuous physical activity, and socioeconomic status,
as well as their weight and height, from which we calculated body mass index (BMI) (weight in kg/height in m$^2$).

We defined incident vascular disease as the first hospital admission with any mention of vascular disease, or, where there was no relevant hospital admission, death with the vascular disease as the underlying cause. We identified a first vascular disease outcome separately for coronary heart disease (ICD-10: I20 to I25), cerebrovascular disease (ICD-10: I60 to I69), ischaemic stroke (ICD-10: I63), and haemorrhagic stroke (ICD-10: I60 to I62). Virtually all residents in the United Kingdom are registered with general practitioners who hold comprehensive information about an individual’s health and medical care in the NHS. We previously reported that there was excellent agreement between vascular disease diagnoses recorded in hospital records and those ascertained from the reports of general practitioners [27].

In a resurvey of the cohort about nine years after baseline recruitment, a randomly selected subgroup of women (N=16,954) provided non-fasting blood samples for lipid profile assessment. Details of blood sample collection, storage and lipid assays have been reported previously [28]. Among this subgroup, some women (N=3694) also had their blood pressure measured at local general practices.

2.1 Statistical analysis

Of the ≈1.3 million women recruited to the study, we excluded 120,905 (8.9%) who reported or had a hospital record of heart disease, stroke or cancer (except non-melanoma skin cancer) before recruitment. Of the remaining 1.2 million women, we further excluded 135,667 (9.9%) who were nulliparous and 2082 (0.2%) with missing data on parity. Data for 1,105,568 parous women with information on hypertension during pregnancy formed the basis of our analysis. We estimated
hazard ratios, hereafter referred to as relative risks, of vascular disease incidence and mortality using Cox regression with age as the underlying time variable. Person-years were calculated from the date of recruitment until date of first hospitalisation, death, emigration and other loss to follow-up, or end of follow-up for this analysis (31 March 2011 in England and 31 December 2008 in Scotland), whichever came first. Around 5% of participants in England were recruited before 1 April 1997. Because hospital admissions data prior to this date were not available, we calculated their follow-up from this date.

All regression models were stratified by geographical region of recruitment (10 UK regions), and the covariates included body mass index (<20, 20 to 24.9, 25 to 29.9, 30 to 34.9 and ≥35 kg/m²), smoking (never smokers, past smokers, and current smokers of <5, 5 to 9, 10 to 14, 15 to 19, 20 to 24 and ≥25 cigarettes per day), socioeconomic status (fifths of Townsend index of deprivation [29]), frequency of strenuous exercise (rarely/never, once a week or less, and more than once a week), weekly alcohol intake (0, 1 to 6, 7 to 14 and ≥15 units), parity (1, 2, 3, 4, and ≥5 children), ever use of hormone replacement therapy (yes or no), and treatment for diabetes (yes vs no), hypercholesterolaemia (yes vs no), and hypertension (yes vs no) at baseline recruitment. Women with missing values for an adjustment variable were assigned to a separate category for that specific variable.

We calculated relative risks separately for each incident vascular disease outcome for all women and by women’s use of anti-hypertensive medication at baseline. We also calculated the risks of death attributed to coronary heart disease and cerebrovascular disease. To examine further the consistency of the risks across different subgroups in the population, we examined the risks of incident coronary heart disease and stroke across a range of characteristics at baseline (socioeconomic status, parity, smoking, body mass index, vigorous exercise frequency, alcoholic
beverage intake, hormone replacement therapy use, treatment for diabetes, and treatment for hypercholesterolaemia at baseline). For women with blood pressure readings and those with lipid profile data measured at around nine years after recruitment, we calculated the age- and region-adjusted mean systolic and diastolic blood pressure, as well as cholesterol and lipid fraction concentrations, according to women’s history of hypertension during pregnancy and use of anti-hypertensive medication at baseline.

We report relative risks with their conventional 95% confidence intervals (CIs). When relative risks for multiple groups are presented (such as when estimating relative risks by joint categories of hypertension during pregnancy and being treated for hypertension in middle age), we report estimates with their 95% group-specific CIs [30] to allow direct comparison of risks between any two categories even if neither is the reference group. We examined heterogeneity in the associations of coronary heart disease and stroke across women’s characteristics using likelihood ratio tests.

We used Stata 14.0 [31] programme to analyse our data, and used Jasper package version 2-210 [32] in R programme [33] to create the figure.
3. Results

In this analysis of over 1.1 million parous women, the mean age at recruitment was 56.0 (SD=4.8) years, and 26.2% (N=290,008) reported that they had high blood pressure during pregnancy. Table 1 shows the characteristics of the participants at baseline. By far, the largest difference between those with and without history of hypertension during pregnancy was the proportion that reported being treated for hypertension at recruitment in their mid-50s: 27% (79,163 of 290,008) of those with a history of hypertensive pregnancy versus 10% (82,145 of 815,560) of those without such a history were on anti-hypertensive medication at recruitment.

Women were followed for 11.6 years (SD=2.3 years) on average, accruing 12.8 million person-years of follow-up. Over this time period, 68,161 women had a first coronary disease event, 22,997 women a cerebrovascular disease, 8365 women an ischaemic stroke, and 5702 women a haemorrhagic stroke, with mean ages at first disease event of 65.0 (SD=6.1), 66.2 (SD=6.6), 66.9 (SD=6.4) and 64.2 (SD=6.6) years, respectively. Of these first vascular disease events, non-fatal hospital admissions accounted for 92% of coronary heart disease, 88% of cerebrovascular disease, 94% of ischaemic stroke, and 79% of haemorrhagic stroke. There were in total 7736 deaths attributed to coronary heart disease and 5554 to cerebrovascular disease, with mean ages at death of 65.9 (SD=6.5) and 66.9 (SD=7.3) years, respectively.

Compared to women without hypertension during pregnancy, the relative risk of a first coronary heart disease event for women with hypertensive pregnancy was 1.29 (95% CI 1.27 to 1.31) (Table 2). For coronary heart disease mortality, the relative risk was 1.35 (95% CI 1.29 to 1.42). The relative risks of a first cerebrovascular disease event or death due to this condition were also increased in women with hypertensive pregnancy. The risks of both ischaemic and haemorrhagic stroke were increased in women with hypertensive disease during pregnancy, with the relative risk
of ischaemic stroke (1.29 [95% CI 1.23 to 1.35]) being slightly greater than the relative risk of haemorrhagic stroke (1.14 [95% CI 1.07 to 1.21]).

Figure 1 shows the relative risks of incident coronary heart disease and stroke across a number of subgroups as defined by the characteristics of women at recruitment. In all the subgroups, the risks of incident coronary heart disease and ischaemic stroke were consistently elevated in women with a history of hypertension during pregnancy. However, for incident coronary heart disease, the risks were somewhat weaker among women being treated for hypercholesterolaemia or diabetes. Nevertheless, these risks remained significantly elevated. We also observed a small increase in haemorrhagic stroke risks across various subgroups with no significant heterogeneity across any subgroup.

As many women who reported a history of hypertension during pregnancy also reported being treated for hypertension at baseline, we compared the risks in women categorised into subgroups as defined by these factors (Table 3). Compared with women with no history of hypertension in pregnancy or in middle age, at study baseline, women who reported treatment for hypertension (but no history of hypertension in pregnancy) had substantially raised subsequent risks of coronary heart disease (relative risk=1.61 [95% CI 1.59 to 1.64]), of ischaemic stroke (relative risk=1.77 [95% CI 1.69 to 1.86]), and of haemorrhagic stroke (relative risk=1.60 [95% CI 1.50 to 1.71]). By contrast, only modest increases in risks were seen in women who had hypertension in pregnancy but not in middle age (relative risks [95% CI] for coronary heart disease, ischaemic and haemorrhagic stroke: 1.17 [1.14 to 1.19], 1.18 [1.11 to 1.25], and 1.09 [1.02 to 1.18], respectively). Women with a history of hypertension both in pregnancy and in middle age had risks either similar to (haemorrhagic stroke) or modestly higher than (coronary heart disease and ischaemic stroke)
those for hypertension in middle age alone. Similar patterns of risk of vascular deaths were seen across these subgroups (Table 4).

In women with information on blood pressure measured around nine years after recruitment (N=3694), systolic and diastolic blood pressure were both elevated in women with hypertension in pregnancy, whether or not they reported being treated for hypertension at study baseline (Table 5). In women with lipid profile assessment (N=18,104), mean plasma concentrations of both total and HDL-cholesterol, as well as apolipoprotein B and A1, were lowest in women who were taking anti-hypertensive medication at baseline (Supplementary table 1). For those who were not on anti-hypertensive treatment, those with a history of hypertension during pregnancy had lower total and HDL-cholesterol, as well as apolipoprotein B and A1, concentrations than those without such history.
4. Discussion

In this large cohort of middle-aged women, hypertension during pregnancy was associated with subsequent increase in risk of vascular disease incidence and mortality. The risks were increased for both coronary heart and cerebrovascular disease, and the risk of stroke was somewhat higher for ischaemic than for haemorrhagic stroke. However, many of these women with a history of hypertensive pregnancy were also being treated for hypertension in their 50s and 60s, and the association on vascular disease risk was substantially greater for being hypertensive in middle age than for having a history of hypertension during pregnancy alone.

Hypertensive disorders in pregnancy are important causes of morbidity and mortality to the mother during the perinatal period [1, 2, 34, 35]. Moreover, mothers with pregnancies complicated by hypertension, such as gestational hypertension or pre-eclampsia, have been reported to have higher risks of later coronary heart [4-6, 8-16] and cerebrovascular disease [5, 7, 9-13, 16] than women with normotensive pregnancies, but many of these studies have mean ages of disease events occurrence at less than 50 years (Web-only supplementary Tables B and C, and Figures A and B), when vascular disease is still relatively uncommon [17, 18]. Compared to women aged 30-49 years in Europe, mortality rates for vascular disease are reported to be three times higher at age 50-59 years, twenty times higher at 60 to 69 years, and 300 times higher at age ≥70 years [17]. This pattern is similarly seen in the US [18]. Although a number of studies have investigated associations between hypertensive disorders during pregnancy and vascular outcomes at around middle age [7, 10, 12, 15, 16] the numbers of disease events were relatively small (Web-only supplementary Tables B and C, and Figures A and B), and the contribution of other risk factors at that age was not examined in detail. In our study, we have shown that in middle age, a history of hypertension during pregnancy is associated with increased coronary heart disease and stroke risks, and these associations are independent of concurrent lifestyle
factors and other potential confounders. Our findings are broadly consistent with other studies that showed elevated risks not just for coronary heart disease but also for cerebrovascular disease in women with hypertensive pregnancies [5, 7, 9-13, 16]. Although one study reported findings based on few ischaemic stroke events [15], the long-term risk of haemorrhagic stroke has not been previously reported. In our study, we showed that both ischaemic and haemorrhagic stroke risks are increased in women with hypertension in pregnancy albeit the magnitude of the risk particularly of haemorrhagic stroke was quite small.

Others have reported that women with hypertensive disorders in pregnancy are at increased risk of high blood pressure many years after the index pregnancy [4, 36]. Our findings suggest that this relation persists into middle age, and could mediate the relation between hypertension during pregnancy and long-term vascular disease risk. For example, the relative risk of coronary heart disease associated with hypertension during pregnancy was 1.29 (95% CI 1.27 to 1.31) (Table 2) compared to those without such history. However, the relative risk was substantially reduced to 1.17 (95% CI 1.14 to 1.19) in women with hypertension during pregnancy who were not on hypertension treatment at baseline (Table 3), suggesting that the risk associated with hypertension during pregnancy appears to be largely explained by hypertension in middle age. Dyslipidaemia may also play a mediating role [37, 38], but the patterns of cholesterol and apolipoproteins concentrations in our cohort do not seem to concur with the observed vascular disease risk estimates with hypertension during pregnancy and being treated for hypertension at study baseline. It is plausible that, at least in our cohort, hypertension appears to play a more important role than dyslipidaemia in mediating the excess vascular disease risk associated with hypertension during pregnancy.
4.1 Limitations

Our study relied on women reporting at the time of their recruitment any hypertension during pregnancy. Although maternal recall of such obstetric history has been reported to have high specificity, the sensitivity is low [39]. In our cohort, a relatively high proportion (26.2%) reported to have ever had high blood pressure during pregnancy than might be expected from the prevalence of clinically-defined hypertensive disorders of pregnancy. Our estimate could reflect the prevalence of hypertension during pregnancy throughout women’s reproductive life as well as hypertensive pregnancies without the clinical features associated with conditions as gestational hypertension or pre-eclampsia. In the prospective Northern Finland Birth Cohort 1966 study (involving >96% expected births in the area), mothers have had their blood pressure measured during maternity clinic visits (93% attended >5 times) [15]. Findings from this study suggest that while the proportions of pre-eclampsia (≈2%) and gestational hypertension (≈8%) were low, the proportion of new-onset hypertension which did not meet the clinical criteria for these disorders was ≈15%, and these phenotypes were shown to be associated with long-term risk of cardiovascular disease. Overall, Männistö and colleagues reported that the proportion of hypertension during pregnancy in their cohort was ≈25% (≈32% if including chronic hypertension). Although we could not rule out recall bias, the proportion of women with hypertension during pregnancy in our study is probably not implausible.

We also did not examine vascular disease risk in relation to specific types of hypertensive disorders in pregnancy as such information was not available. These different types may have varying effect sizes, with more severe forms likely to be associated with greater magnitude of vascular disease risk [4], so our risk estimates may underestimate the actual risks associated with some of these specific hypertensive disorders in pregnancy. It is also possible that some of the vascular disease events which occurred prior to study participation may be related to
hypertension during pregnancy. However, differential reporting of obstetric history may exist between those with and without prevalent vascular disease so we excluded those with known vascular disease at baseline from the analysis. We adjusted for a number of potential confounders, but as an observational study, we could not rule out residual confounding. Nevertheless, our study is based on a large number of vascular disease events, including stroke events according to subtype, allowing us to examine in detail the associations with different vascular disease phenotypes at ages when the vascular disease burden in women is high.

4.2 Conclusion

In this large cohort of middle-aged women, hypertension during pregnancy was associated with increased risks of coronary heart disease and stroke. However, the risk of vascular disease associated with being hypertensive in middle age was greater than that associated with a history of hypertension during pregnancy alone. Since many of the women with a history of hypertension during pregnancy were also hypertensive in their 50s and 60s, the associations between history of hypertensive pregnancy with coronary heart disease and stroke are likely to be explained by increased blood pressure in middle age. Controlling hypertension is likely to be beneficial to middle-aged women, including those with hypertension during pregnancy. But efforts to prevent women with hypertensive pregnancy from developing hypertension by middle age may be just as important to help reduce their risk of developing vascular disease in the long-term.
**Author contributions**

VB, GR, and JG were involved in the conception, design of the study, and acquisition of data for the Million Women Study. DC, AB, and VB analysed the data. DC, BJC, AB, FLW, AK, JG, VB, and GR interpreted the data. DC drafted the first version of the manuscript. BJC, AB, FLW, AK, JG, VB, and GR gave critical intellectual input, and contributed in drafting revised versions of the manuscript. All authors gave their final approval of the version to be published.

**Acknowledgement**

We thank the women who participated in the Million Women Study. We also thank the Information Services Division in Scotland and the NHS Information Centre for Health and Social Care in England for the hospital admissions data, the staff at general practices throughout the UK for their help in collecting blood samples, as well as our collaborators listed as follows:

*The Million Women Study Co-ordinating Centre staff:* Hayley Abbiss, Simon Abbott, Rupert Alison, Naomi Allen, Miranda Armstrong, Krys Baker, Angela Balkwill, Emily Banks, Isobel Barnes, Valerie Beral, Judith Black, Roger Blanks, Kathryn Bradbury, Anna Brown, Benjamin Cairns, Karen Canfell, Dexter Canoy, Andrew Chadwick, Barbara Crossley, Francesca Crowe, Dave Ewart, Sarah Ewart, Lee Fletcher, Sarah Floud, Toral Gathani, Laura Gerrard, Adrian Goodill, Jane Green, Lynden Guiver, Michal Hozák, Isobel Lingard, Sau Wan Kan, Oksana Kirichek, Nicky Langston, Bette Liu, Kath Moser, Kirstin Pirie, Gillian Reeves, Keith Shaw, Emma Sherman, Helena Strange, Siân Sweetland, Sarah Tipper, Ruth Travis, Lyndsey Trickett, F Lucy Wright, Owen Yang, and Heather Young.

*The Advisory Committee:* Emily Banks, Valerie Beral, Lucy Carpenter, Carol Dezateux, Jane Green, Julietta Patnick, Richard Peto, and Cathie Sudlow.
The NHS Breast Screening Centres which took part in the recruitment and breast screening follow up: Avon, Aylesbury, Barnsley, Basingstoke, Bedfordshire and Hertfordshire, Cambridge and Huntingdon, Chelmsford and Colchester, Chester, Cornwall, Crewe, Cumbria, Doncaster, Dorset, East Berkshire, East Cheshire, East Devon, East of Scotland, East Suffolk, East Sussex, Gateshead, Gloucestershire, Great Yarmouth, Hereford and Worcester, Kent, Kings Lynn, Leicestershire, Liverpool, Manchester, Milton Keynes, Newcastle, North Birmingham, North East Scotland, North Lancashire, North Middlesex, North Nottingham, North of Scotland, North Tees, North Yorkshire, Nottingham, Oxford, Portsmouth, Rotherham, Sheffield, Shropshire, Somerset, South Birmingham, South East Scotland, South East Staffordshire, South Derbyshire, South Essex, South Lancashire, South West Scotland, Surrey, Warrington Halton St Helens and Knowsley, Warwickshire Solihull and Coventry, West Berkshire, West Devon, West London, West Suffolk, West Sussex, Wiltshire, Winchester, Wirral, and Wycombe.
References

[1] WHO Study Group. The Hypertensive Disorders of Pregnancy. Technical Series Report 785. World Health Organization: Geneva, 1987.

[2] Creanga AA, Berg CJ, Syverson C, Seed K, Bruce FC, Callaghan WM. Pregnancy-related mortality in the United States, 2006-2010. Obstet Gynecol. 2015;125:5-12. doi:10.1097/AOG.0000000000000564

[3] Ananth CV, Peedicayil A, Savitz DA. Effect of hypertensive diseases in pregnancy on birthweight, gestational duration, and small-for-gestational-age births. Epidemiology. 1995;6:391-395.

[4] Bellamy L, Casas JP, Hingorani AD, Williams DJ. Pre-eclampsia and risk of cardiovascular disease and cancer in later life: systematic review and meta-analysis. BMJ. 2007;335:974. doi:10.1136/bmj.39335.385301.BE

[5] Hannaford P, Ferry S, Hirsch S. Cardiovascular sequelae of toxaemia of pregnancy. Heart. 1997;77:154-158.

[6] Smith GC, Pell JP, Walsh D. Pregnancy complications and maternal risk of ischaemic heart disease: a retrospective cohort study of 129,290 births. Lancet. 2001;357:2002-2006. doi:10.1016/S0140-6736(00)05112-6

[7] Wilson BJ, Watson MS, Prescott GJ, et al. Hypertensive diseases of pregnancy and risk of hypertension and stroke in later life: results from cohort study. BMJ. 2003;326:845. doi:10.1136/bmj.326.7394.845

[8] Wikstrom AK, Haglund B, Olovsson M, Lindeberg SN. The risk of maternal ischaemic heart disease after gestational hypertensive disease. BJOG. 2005;112:1486-1491. doi:10.1111/j.1471-0528.2005.00733.x

[9] Ray JG, Vermeulen MJ, Schull MJ, Redelmeier DA. Cardiovascular health after maternal placental syndromes (CHAMPS): population-based retrospective cohort study. Lancet. 2005;366:1797-1803. doi:10.1016/S0140-6736(05)67726-4

[10] Arnadottir GA, Geirsson RT, Arngrimsson R, Jonsdottir LS, Olafsson O. Cardiovascular death in women who had hypertension in pregnancy: a case-control study. BJOG. 2005;112:286-292. doi:10.1111/j.1471-0528.2004.00396.x
[11] Lykke JA, Langhoff-Roos J, Sibai BM, Funai EF, Triche EW, Paidas MJ. Hypertensive pregnancy disorders and subsequent cardiovascular morbidity and type 2 diabetes mellitus in the mother. Hypertension. 2009;53:944-951. doi:10.1161/HYPERTENSIONAHA.109.130765

[12] Bhattacharya S, Prescott GJ, Iversen L, Campbell DM, Smith WC, Hannaford PC. Hypertensive disorders of pregnancy and future health and mortality: A record linkage study. Pregnancy Hypertens. 2012;2:1-7. doi:10.1016/j.preghy.2011.08.116

[13] Skjærven R, Wilcox AJ, Klungsoyr K, et al. Cardiovascular mortality after pre-eclampsia in one child mothers: prospective, population based cohort study. BMJ. 2012;345:e7677. doi:10.1136/bmj.e7677

[14] Zhao HY, Chen XW, Niu JQ, et al. [History of pregnancy induced hypertension is linked with increased risk of cardio-cerebral vascular events]. Zhonghua Xin Xue Guan Bing Za Zhi. 2012;40:645-651.

[15] Männistö T, Mendola P, Vääräsmäki M, et al. Elevated blood pressure in pregnancy and subsequent chronic disease risk. Circulation. 2013;127:681-690. doi:10.1161/CIRCULATIONAHA.112.128751

[16] Heida KY, Franx A, van Rijn BB, et al. Earlier age of onset of chronic hypertension and type 2 diabetes mellitus after a hypertensive disorder of pregnancy or gestational diabetes mellitus. Hypertension. 2015;66:1116-1122. doi:10.1161/HYPERTENSIONAHA.115.06005

[17] World Health Organization. Global health estimates 2014 summary tables: deaths by cause, age and sex, by WHO region, 2000-2012. http://www.who.int/healthinfo/global_burden_disease/en/ (accessed 29 Feb 2016).

[18] Centers for Disease Control and Prevention, National Center for Health Statistics. Underlying cause of death 1999-2013. CDC WONDER online database, released 2015, from the Multiple Cause of Death Files, 1999-2013, as compiled from data provided by the 57 vital statistics jurisdictions through the Vital Statistics Cooperative Program. http://wonder.cdc.gov/ucd-icd10.html (accessed 29 Feb 2016).

[19] Mozaffarian D, Benjamin EJ, Go AS, et al. Heart disease and stroke statistics-2016 update: A report from the American Heart Association. Circulation. 2016;133:e38-e360. doi:10.1161/CIR.0000000000000350

[20] Townsend N, Williams J, Bhatnagar P, Wickramasinghe K, Rayner M. Cardiovascular disease statistics 2014. British Heart Foundation: London, 2014.

[21] The Million Women Study. http://www.millionwomenstudy.org/introduction/ (accessed 29 Feb 2016).
[22] Health and Social Care Information Centre. [http://www.hscic.gov.uk/](http://www.hscic.gov.uk/) (accessed 29 Feb 2016).

[23] National Records of Scotland. NHS Central Register. [http://www.nrscotland.gov.uk/statistics-and-data/nhs-central-register](http://www.nrscotland.gov.uk/statistics-and-data/nhs-central-register) (accessed 29 Feb 2016).

[24] Health and Social Care Information Centre. Hospital Episode Statistics. [http://www.hscic.gov.uk/hes](http://www.hscic.gov.uk/hes) (accessed 29 Feb 2016).

[25] Administrative Data Liaison Service. Scottish Morbidity Records. [http://www.adls.ac.uk/nhs-scotland/scottish-morbidity-database-smr/?detail](http://www.adls.ac.uk/nhs-scotland/scottish-morbidity-database-smr/?detail) (accessed 29 Feb 2016).

[26] World Health Organization. International Statistical Classification of Diseases and Related Health Problems 10th Revision. [http://apps.who.int/classifications/icd10/](http://apps.who.int/classifications/icd10/) (accessed 29 Feb 2016).

[27] Wright FL, Green J, Canoy D, et al. Vascular disease in women: comparison of diagnoses in hospital episode statistics and general practice records in England. BMC Med Res Methodol. 2012;12:161. doi:10.1186/1471-2288-12-161

[28] Canoy D, Beral V, Balkwill A, et al. Age at menarche and risks of coronary heart and other vascular diseases in a large UK cohort. Circulation. 2015;131:237-244. doi:10.1161/CIRCULATIONAHA.114.010070

[29] Townsend P, Phillimore P, Beattie A. Health and Deprivation: Inequality and the North. Beckenham: Croom Helm Ltd., 1988.

[30] Plummer M. Improved estimates of floating absolute risk. Stat Med. 2004;23:93-104. doi:10.1002/sim.1485

[31] Stata MP, 13.0. College Station, TX, USA: StataCorp, 2013.

[32] Arnold M. Jasper: Jasper makes plots, R package version 2-210. Oxford, UK: 2016.

[33] R Development Core Team. R: A language and environment for statistical computing, Vienna, Austria: R Foundation for Statistical Computing, 2016.

[34] Kuklina EV, Ayala C, Callaghan WM. Hypertensive disorders and severe obstetric morbidity in the United States. Obstet Gynecol. 2009;113:1299-1306. doi:10.1097/AOG.0b013e3181a45b25

[35] Bramham K, Parnell B, Nelson-Piercy C, Seed PT, Poston L, Chappell LC. Chronic hypertension and pregnancy outcomes: systematic review and meta-analysis. BMJ. 2014;348:g2301. doi:10.1136/bmj.g2301
[36] Garovic VD, August P. Preeclampsia and the future risk of hypertension: the pregnant evidence. Curr Hypertens Rep. 2013;15:114-121. doi:10.1007/s11906-013-0329-4

[37] Magnussen EB, Vatten LJ, Smith GD, Romundstad PR. Hypertensive disorders in pregnancy and subsequently measured cardiovascular risk factors. Obstet Gynecol. 2009;114:961-970. doi:10.1097/AOG.0b013e3181bb0dfc

[38] Fanshawe AE, Ibrahim M. The current status of lipoprotein (a) in pregnancy: a literature review. J Cardiol. 2013;61:99-106. doi:10.1016/j.jjcc.2012.09.009

[39] Stuart JJ, Bairey Merz CN, Berga SL, et al. Maternal recall of hypertensive disorders in pregnancy: a systematic review. J Womens Health (Larchmt). 2013;22:37-47. doi:10.1089/jwh.2012.3740
Figure legend

Figure 1. Relative risks (95% group-specific confidence interval) of incident coronary heart disease, ischaemic stroke, and haemorrhagic stroke in parous women with reported hypertension during pregnancy (N=290,008) as compared to women without such history (N=815,560), by their characteristics at baseline. Relative risks are hazard ratios estimated using Cox regression with age as the underlying time variable, stratified by region of recruitment, and adjusted for all listed factors except when the characteristic is under consideration. The area of the square is inversely proportional to the variance of the log risk. RR – relative risk; g-sCI – group-specific confidence interval; ICD-10 – International Classification of Diseases, 10th Revision.
Table 1. Characteristics of parous women, by reported history of hypertension during pregnancy.

| Characteristics at baseline | Hypertension during pregnancy | All parous women |
|-----------------------------|-------------------------------|------------------|
|                             | No N=815,560                  | Yes N=290,008    | N=1,105,568 |
| Age (years), mean(SD)       | 56.0 (4.8)                    | 55.9 (4.7)       | 56.0 (4.8) |
| Body mass index (kg/m²), mean (SD) | 25.8 (4.4)                  | 27.3 (5.1)       | 26.2 (4.6) |
| Age at menarche (years), mean (SD) | 13.1 (1.6)                  | 12.8 (1.6)       | 13.0 (1.6) |
| Parity, mean (SD)           | 2.4 (1.0)                     | 2.4 (1.1)        | 2.4 (1.0)  |
| % Current smoker (N)        | 21.9 (168,229)                | 17.6 (47,952)    | 20.8 (216,173) |
| % Non-drinker of alcoholic beverages (N) | 28.9 (187,388)          | 30.3 (69,220)    | 29.3 (256,608) |
| % Engage in vigorous exercise ≤1 per week (N) | 47.9 (376,209)         | 48.2 (134,897)   | 48.0 (511,106) |
| % Lowest third of socioeconomic status (N) | 32.8 (265,143)          | 32.4 (93,354)    | 32.7 (358,497) |
| % Ever use of hormone replacement therapy (N) | 51.4 (414,502)           | 49.7 (142,411)   | 51.0 (556,913) |
| % Being treated for hypertension (N) | 10.1 (82,145)             | 27.3 (79,163)    | 14.6 (161,308) |
| % Being treated for diabetes (N) | 1.7 (14,164)               | 3.0 (8646)       | 2.1 (22,810) |
| % Being treated for hypercholesterolaemia (N) | 2.3 (18,552)              | 3.5 (10,126)     | 2.6 (28,678) |
| Follow-up details           |                               |                  |             |
| First vascular disease event (ICD-10), no. (person-years [1000s]) |                       |                  |             |
| Coronary heart disease (I20 to I25) | 46,580 (9449)             | 21,581 (3333)    | 68,161 (12,782) |
| Cerebrovascular disease (I60 to I69) | 16,226 (9600)            | 6771 (3408)      | 22,997 (13,008) |
| Ischaemic stroke (I63)      | 5784 (9635)                | 2581 (3422)      | 8365 (13,057) |
| Haemorrhagic stroke (I60 to I62) | 4164 (9641)               | 1538 (3426)      | 5702 (13,067) |
| Underlying cause of death (ICD-10), no. (person-years [1000s]) |                       |                  |             |
| Coronary heart disease (I20 to I25) | 5216 (11,850)             | 2520 (4219)      | 7736 (16,068) |
| Cerebrovascular disease (I60 to I69) | 4032 (11,850)            | 1522 (4219)      | 5554 (16,068) |

ICD-10 – International Classification of Diseases, 10th Revision.
Table 2. Relative risks (95% confidence interval) of vascular disease in parous women, by reported history of hypertension during pregnancy.

| Vascular disease (ICD-10) | No. with vascular disease outcome | Relative risk (95% confidence interval) |
|---------------------------|----------------------------------|----------------------------------------|
|                           | Hypertension during pregnancy     |                                        |
|                           | Yes (N=290,008)                  |                                        |
|                           | No (N=815,560)                   |                                        |
| **First vascular disease event** |                              |                                        |
| Coronary heart disease (I20 to I25) | 21,581                        | 46,580                                 |
| Cerebrovascular disease (I60 to I69) | 6771                          | 16,226                                 |
| Ischaemic stroke (I63)   | 2581                            | 5784                                   |
| Haemorrhagic stroke (I60 to I62) | 1538                          | 4164                                   |
| **Underlying cause of death** |                              |                                        |
| Coronary heart disease (I20 to I25) | 2520                          | 5216                                   |
| Cerebrovascular disease (I60 to I69) | 1522                          | 4032                                   |

ICD-10 – International Classification of Diseases, 10th Revision; Relative risks based on Cox regression with age as the underlying time variable; Risk estimates stratified by region of recruitment, and adjusted for smoking, socioeconomic status, exercise, alcohol intake, body mass index, parity, ever use of hormone replacement therapy, treatment for diabetes, and treatment for hypercholesterolaemia at baseline.
Table 3. Relative risk (95% group-specific confidence interval [g-sCi]) of incident coronary heart disease and stroke in parous women, by reported history of hypertension during pregnancy and treatment for hypertension at baseline.

| Incident vascular disease (ICD-10) | Hypertension during pregnancy | Being treated for hypertension at baseline | No. with outcome | Relative risk (95% g-sCi) |
|----------------------------------|-------------------------------|------------------------------------------|-----------------|--------------------------|
| Coronary heart disease (I20 to I25) |                               |                                          |                 |                          |
| No                               | No                            | 33,884                                   | 1.00 (0.99 to 1.01) |
| Yes                              | No                            | 8999                                     | 1.17 (1.14 to 1.19) |
| No                               | Yes                           | 12,696                                   | 1.61 (1.59 to 1.64) |
| Yes                              | Yes                           | 12,582                                   | 1.78 (1.76 to 1.82) |
| Ischaemic stroke (I63)           |                               |                                          |                 |                          |
| No                               | No                            | 4077                                     | 1.00 (0.97 to 1.03) |
| Yes                              | No                            | 1056                                     | 1.18 (1.11 to 1.25) |
| No                               | Yes                           | 1707                                     | 1.77 (1.69 to 1.86) |
| Yes                              | Yes                           | 1525                                     | 1.86 (1.76 to 1.96) |
| Haemorrhagic stroke (I60 to I62) |                               |                                          |                 |                          |
| No                               | No                            | 3184                                     | 1.00 (0.96 to 1.04) |
| Yes                              | No                            | 760                                      | 1.09 (1.02 to 1.18) |
| No                               | Yes                           | 980                                      | 1.60 (1.50 to 1.71) |
| Yes                              | Yes                           | 778                                      | 1.48 (1.38 to 1.59) |

ICD-10 – International Classification of Diseases, 10th Revision; Relative risks are hazard ratios estimated using Cox regression with age as the underlying time variable, stratified by region of recruitment, and adjusted for smoking, socioeconomic status, exercise, alcohol intake, body mass index, parity, ever use of hormone replacement therapy, treatment for diabetes, and treatment for hypercholesterolaemia at baseline; Reference group: no history of hypertensive pregnancy and not on anti-hypertensive treatment at baseline.
Table 4. Relative risk (95% group-specific confidence interval [g-sCI]) of coronary heart and cerebrovascular disease mortality in parous women, by reported history of hypertension during pregnancy and treatment for hypertension at baseline.

| Underlying cause of death (ICD-10) | Hypertension during pregnancy | Being treated for hypertension at baseline | No. with outcome | Relative risk (95% g-sCI) |
|-----------------------------------|-----------------------------|------------------------------------------|-----------------|-------------------------|
| Coronary heart disease (I20 to I25) |                             |                                          |                 |                         |
| No                                | No                          | 3582                                    | 1.00 (0.97 to 1.04) |
| Yes                               | No                          | 967                                     | 1.23 (1.16 to 1.31) |
| No                                | Yes                         | 1634                                    | 1.86 (1.77 to 1.96) |
| Yes                               | Yes                         | 1553                                    | 2.02 (1.92 to 2.14) |
| Cerebrovascular disease (I60 to I69) |                             |                                          |                 |                         |
| No                                | No                          | 2848                                    | 1.00 (0.96 to 1.04) |
| Yes                               | No                          | 658                                     | 1.10 (1.02 to 1.18) |
| No                                | Yes                         | 1184                                    | 1.88 (1.78 to 1.99) |
| Yes                               | Yes                         | 864                                     | 1.69 (1.58 to 1.81) |

ICD-10 – International Classification of Diseases, 10th Revision; Relative risks are hazard ratios estimated using Cox regression with age as the underlying time variable, stratified by region of recruitment, and adjusted for smoking, socioeconomic status, exercise, alcohol intake, body mass index, parity, ever use of hormone replacement therapy, treatment for diabetes, and treatment for hypercholesterolaemia at baseline; Reference group: no history of hypertensive pregnancy and not on anti-hypertensive treatment at baseline.
Table 5. Mean blood pressure (95% confidence interval [CI]) at resurvey in 3694 women, by reported history of hypertension during pregnancy and treatment of hypertension at baseline.

| Hypertension during pregnancy | Being treated for hypertension at baseline | No. of women | Mean systolic blood pressure (mmHg) at resurvey (95% CI) | Mean diastolic blood pressure (mmHg) at resurvey (95% CI) |
|-------------------------------|------------------------------------------|--------------|--------------------------------------------------------|--------------------------------------------------------|
| No                            | No                                       | 2636         | 132.9 (132.3 to 133.6)                                  | 77.3 (77.0 to 77.7)                                     |
| Yes                           | No                                       | 631          | 137.9 (136.7 to 139.2)                                  | 79.9 (79.2 to 80.6)                                     |
| No                            | Yes                                      | 247          | 139.7 (137.7 to 141.7)                                  | 80.3 (79.1 to 81.5)                                     |
| Yes                           | Yes                                      | 180          | 139.0 (136.6 to 141.3)                                  | 79.5 (78.2 to 80.9)                                     |

Mean blood pressure adjusted for age at blood pressure measurement and region of recruitment; Resurvey at nine years, on average, after baseline recruitment.
| Characteristics | CORONARY HEART DISEASE (I20 TO I25) | ISCHAEMIC STROKE (I63) | HAEMORRHAGIC STROKE (I60 TO I62) |
|-----------------|----------------------------------|------------------|----------------------------------|
|                  | Hypertension during pregnancy (No. of events) | Hypertension during pregnancy (No. of events) | Hypertension during pregnancy (No. of events) |
| Socioeconomic status | No | Yes | RR (95% g−sCI) | No | Yes | RR (95% g−sCI) | No | Yes | RR (95% g−sCI) |
| High             | 18,755 | 9915 | 1.33 (1.29, 1.36) | 2374 | 1090 | 1.30 (1.21, 1.40) | 1886 | 701 | 1.13 (1.04, 1.24) |
| Low              | 27,825 | 12,566 | 1.26 (1.24, 1.29) | 3410 | 1491 | 1.28 (1.20, 1.36) | 2278 | 837 | 1.14 (1.05, 1.24) |
|                 | Heterogeneity: χ² (2) (p<0.001) | χ² (2) (p<0.01) | χ² (2) (p<0.01) | χ² (2) (p<0.01) | χ² (2) (p<0.01) | χ² (2) (p<0.01) |
| Parity           | No | Yes | RR (95% g−sCI) | No | Yes | RR (95% g−sCI) |
| 1 to 2           | 26,466 | 11,581 | 1.29 (1.27, 1.32) | 3347 | 1392 | 1.27 (1.19, 1.36) |
| 3 or more        | 20,134 | 10,000 | 1.29 (1.26, 1.32) | 2437 | 1189 | 1.31 (1.22, 1.41) |
|                 | Heterogeneity: χ² (2) (p=0.7) | χ² (2) (p=0.5) | χ² (2) (p=0.5) | χ² (2) (p=0.5) | χ² (2) (p=0.5) | χ² (2) (p=0.5) |
| Current smokers  | No | Yes | RR (95% g−sCI) | No | Yes | RR (95% g−sCI) |
|                  | 29,147 | 14,797 | 1.29 (1.26, 1.31) | 3462 | 1706 | 1.28 (1.21, 1.36) |
|                 | Heterogeneity: χ² (2) (p=0.4) | χ² (2) (p=0.7) | χ² (2) (p=0.7) | χ² (2) (p=0.7) | χ² (2) (p=0.7) | χ² (2) (p=0.7) |
| Body mass index (kg/m²) | No | Yes | RR (95% g−sCI) | No | Yes | RR (95% g−sCI) |
| <25              | 17,532 | 5862 | 1.33 (1.29, 1.37) | 2334 | 793 | 1.38 (1.27, 1.49) |
| 25 or higher     | 26,107 | 14,367 | 1.29 (1.27, 1.32) | 3076 | 1575 | 1.22 (1.15, 1.30) |
|                 | Heterogeneity: χ² (2) (p<0.01) | χ² (2) (p<0.01) | χ² (2) (p<0.01) | χ² (2) (p<0.01) | χ² (2) (p<0.01) | χ² (2) (p<0.01) |
| Engage in strenuous exercise | No | Yes | RR (95% g−sCI) | No | Yes | RR (95% g−sCI) |
| Rarely/never     | 25,869 | 11,673 | 1.27 (1.24, 1.30) | 3308 | 1400 | 1.36 (1.18, 1.54) |
| Once a week or more | 18,209 | 8824 | 1.33 (1.29, 1.36) | 2241 | 1035 | 1.32 (1.23, 1.43) |
|                 | Heterogeneity: χ² (2) (p=0.01) | χ² (2) (p=0.3) | χ² (2) (p=0.3) | χ² (2) (p=0.3) | χ² (2) (p=0.3) | χ² (2) (p=0.3) |
| Alcohol beverage drinker | No | Yes | RR (95% g−sCI) | No | Yes | RR (95% g−sCI) |
|                  | 15,244 | 7130 | 1.27 (1.23, 1.30) | 1815 | 830 | 1.28 (1.18, 1.39) |
|                 | Heterogeneity: χ² (2) (p<0.01) | χ² (2) (p<0.01) | χ² (2) (p<0.01) | χ² (2) (p<0.01) | χ² (2) (p<0.01) | χ² (2) (p<0.01) |
| Ever use of hormone treatment | No | Yes | RR (95% g−sCI) | No | Yes | RR (95% g−sCI) |
|                  | 21,035 | 10,114 | 1.30 (1.27, 1.33) | 2993 | 1374 | 1.29 (1.21, 1.37) |
|                 | Heterogeneity: χ² (2) (p<0.01) | χ² (2) (p<0.01) | χ² (2) (p<0.01) | χ² (2) (p<0.01) | χ² (2) (p<0.01) | χ² (2) (p<0.01) |
| Diabetes treatment at baseline | No | Yes | RR (95% g−sCI) | No | Yes | RR (95% g−sCI) |
|                  | 43,951 | 19,750 | 1.30 (1.28, 1.32) | 5472 | 2339 | 1.28 (1.22, 1.35) |
|                 | Heterogeneity: χ² (2) (p<0.01) | χ² (2) (p<0.01) | χ² (2) (p<0.01) | χ² (2) (p<0.01) | χ² (2) (p<0.01) | χ² (2) (p<0.01) |
| Hypercholesterolemia treatment at baseline | No | Yes | RR (95% g−sCI) | No | Yes | RR (95% g−sCI) |
|                  | 44,205 | 20,099 | 1.30 (1.28, 1.32) | 5564 | 2441 | 1.29 (1.23, 1.36) |
|                 | Heterogeneity: χ² (2) (p<0.01) | χ² (2) (p<0.01) | χ² (2) (p<0.01) | χ² (2) (p<0.01) | χ² (2) (p<0.01) | χ² (2) (p<0.01) |
| ALL WOMEN        | 46,577 | 21,574 | 1.29 (1.27, 1.31) | 5784 | 2581 | 1.29 (1.23, 1.35) | 4164 | 1538 | 1.14 (1.07, 1.21) |
WEB-ONLY SUPPLEMENT

Hypertension in pregnancy and risk of coronary heart disease and stroke: a prospective study in a large UK cohort

D Canoy\textsuperscript{a}, BJ Cairns\textsuperscript{a}, A Balkwill\textsuperscript{b}, FL Wright\textsuperscript{a}, A Khalili\textsuperscript{b}, V Beral\textsuperscript{a}, J Green\textsuperscript{a}, and G Reeves\textsuperscript{a} for the Million Women Study Collaborators

\textsuperscript{a}Cancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK

\textsuperscript{b}Department of Obstetrics and Gynaecology, St. George’s Medical School, University of London, London, UK

CONTENTS:

Table A. Mean plasma concentrations of cholesterol and lipid fractions at resurvey in 18,104 women, by history of hypertension during pregnancy and treatment for hypertension at baseline................................................................................................................................................................................................. Page 2

Table B. Prospective studies investigating the relation between hypertension during pregnancy and coronary heart disease risk............................................................................................................................... Page 3

Table C. Prospective studies investigating the relation between hypertension during pregnancy and cerebrovascular disease risk.................................................................................................................. Page 5

Figure A. Estimated women’s ages at the beginning and end of follow-up of prospective studies investigating the relation between hypertension during pregnancy and coronary heart disease risk........................................................................................................................................ Page 7

Figure B. Estimated women’s ages at the beginning and end of follow-up of prospective studies investigating the relation between hypertension during pregnancy and cerebrovascular disease risk........................................................................................................................................ Page 8

References.................................................................................................................................................................................................................. Page 9
Table A. Mean plasma concentrations of cholesterol and lipid fractions (95% confidence interval) at resurvey in 18,104 women, by history of hypertension during pregnancy and treatment for hypertension at baseline.

| Hypertension during pregnancy | Being treated for hypertension at baseline | No. of women | Total cholesterol (mmol/L) | HDL-cholesterol (mmol/L) | Apolipoprotein B (g/L) | Apolipoprotein A<sub>1</sub> (g/L) | Apolipoprotein B to A<sub>1</sub> ratio |
|------------------------------|------------------------------------------|--------------|---------------------------|--------------------------|------------------------|-------------------------|----------------------------------|
| No                           | No                                       | 12,888       | 5.90 (5.87 to 5.91)       | 1.64 (1.63 to 1.64)      | 1.08 (1.07 to 1.08)    | 1.72 (1.71 to 1.72)     | 0.64 (0.64 to 0.65)                |
| Yes                          | No                                       | 3129         | 5.79 (5.75 to 5.83)       | 1.59 (1.57 to 1.60)      | 1.06 (1.06 to 1.07)    | 1.69 (1.68 to 1.70)     | 0.65 (0.64 to 0.65)                |
| No                           | Yes                                      | 1167         | 5.35 (5.29 to 5.41)       | 1.49 (1.46 to 1.51)      | 0.99 (0.98 to 1.01)    | 1.65 (1.63 to 1.66)     | 0.62 (0.61 to 0.63)                |
| Yes                          | Yes                                      | 920          | 5.35 (5.27 to 5.42)       | 1.46 (1.43 to 1.49)      | 1.00 (0.99 to 1.02)    | 1.63 (1.61 to 1.65)     | 0.63 (0.62 to 0.64)                |

Mean lipid concentration adjusted for age at blood collection and region of recruitment; Resurvey at nine years, on average, after baseline recruitment.
### Table B. Prospective studies investigating the relation between hypertension during pregnancy and coronary heart disease risk.

| Author / Country / Year | Study population | Type of exposure | Source of exposure data | No. of participants | No. of events | Year of study entry & exit | Mean follow-up duration from index pregnancy or study (years) | Mean age (years) at baseline [at outcome] | Relative risk | Comments |
|-------------------------|-------------------|------------------|-------------------------|---------------------|--------------|---------------------------|-------------------------------------------------------------|------------------------------------------|----------------|----------|
| Männistö (Finland); 2013 | Mothers of offspring in a population-based birth cohort | Chronic & new-onset hypertension (e.g. isolated, gestational & pre-eclampsia) | Questionnaires at maternity clinic & linkage with antenatal records | 10,314 | 1875 CHD; 778 incident MI; 206 MI deaths | 1966 until ≈2006 | Mean= 39.4 ≈26 [66.7] | From 1.26 to 5.12 (higher RRs for more severe exposure and outcome phenotypes) | Reference group: normotensive pregnancies; RR adjusted for perinatal factors |
| Skjærven (Norway); 2012 | Mothers with deliveries recorded in a national birth registry | Pre-eclampsia | Retrospective review of birth registry | 836,147 | 1086 CHD deaths | 1967 to 2002 until 2009 | Median= 25 24.3 [49.1*] | 1.7 to 9.3, with higher risks for preterm births and lower risks for ≥2 lifetime pregnancies | Reference group: ≥2 lifetime pregnancies & no pre-eclampsia; RR adjusted for perinatal & reproductive factors |
| Bhattacharya (Scotland); 2012 | Mothers with deliveries recorded in population-based birth registry | Gestational hypertension & pre-eclampsia (including eclampsia) | Retrospective review of maternity and birth registers | 34,854 | 733 CHD deaths; 2810 incident CHD | From 1950 to 2008 | Up to 58 years (mean ≈40) =24 [=64 at death] | For pre-eclampsia, 1.18 (NS) for incident CHD, 1.38 for CHD death; for gestational hypertension, 1.22 for incident CHD, 1.35 for CHD death | Hospitalisations not modelled as incident outcomes; Risk estimates are odds ratios |
| Lykke (Denmark); 2009 | Mothers with deliveries recorded in a national birth registry | Gestational hypertension & pre-eclampsia | Retrospective review of birth registry | 782,287 | 8516 incident CHD | 1978 to 2007 until 2008 | Mean= 14.6 26.8 [41.6] | From 1.48 to 1.61; higher RRs with pregnancy complications & repeated pre-eclampsia | Reference group: no hypertensive pregnancy; RR adjusted for perinatal factors (but not for body size or smoking during pregnancy) |
| Arnadottir (Iceland); 2005 | Mothers with deliveries recorded in a single hospital (undefined catchment area) | Chronic hypertension, gestational hypertension, pre-eclampsia & eclampsia | Retrospective review of maternity records | 325 exposed, 629 unexposed | 171 CHD deaths | 1931 to 1947 until 1996 | Median= 50 (exposed group), 55 (unexposed group) Either ages not mentioned | 1.66; Unadjusted CHD death rates increased with pre-eclampsia severity (p=0.02); NS for chronic hypertension only | Exposed group matched for date of delivery, parity, and age at pregnancy; RR unadjusted for other covariates |
| Ray (Canada); 2005 | Nulliparous mothers with deliveries recorded in province-wide health insurance database | Maternal placental syndrome | Retrospective review of health insurance database | 1,026,265 | 1440 incident CHD | From 1990 to 2004 | Median= 8.7 28 [38.3] 2.0 (1.7 to 2.3) | Reference group: No maternal placental syndrome; RR adjusted for perinatal factors and medical history including gestational diabetes, & history of hypertension or dyslipidaemia |
| Study | Country | Participants | Hypertension | Study Design | Records Reviewed | Incident CHD | CHD Deaths | Follow-Up Period | Age at Event | RR | Reference Group | RR Adjusted for | Notes |
|-------|---------|--------------|--------------|--------------|----------------|--------------|-------------|----------------|-------------|-----|-----------------|----------------|-------|
| Wikstrom | Sweden; 2005 | Mothers with deliveries recorded in a national birth registry | Gestational hypertension & pre-eclampsia | Retrospective review of national birth registry | 403,550 | 2579 incident CHD | 1973 to 1982, followed from 1987 to 2001 | 19 to 28 (at least 15 years) | 85% within 25 to 44 [Median= 48] | From 1.6 to 2.8; RR increases in relation to parity and co-occurring pregnancy complications | Included only those without diabetes or chronic hypertension during pregnancy; Reference group: Non-hypertensive first pregnancy; RR adjusted for some perinatal factors |
| Wilson | Scotland; 2003 | Mothers with deliveries recorded in population-based birth registry, & traced for assessment for this study | Gestational hypertension & pre-eclampsia | Retrospective review of maternity and birth registers | 3593 | 138 incident CHD, 53 CHD deaths | 1951 to 1970 for events occurring between 1980 & 1999 | Not mentioned | 24 [possibly between 53 and 68] | NS | No prior hypertension during index pregnancy; Reference group: No hypertension during pregnancy; Exposed group matched by age at delivery & birth year to unexposed group; RR adjusted for some perinatal factors |
| Smith | Scotland; 2001 | Nulliparous mothers with deliveries are recorded in national health database | Pre-eclampsia | Retrospective review of maternity health records | 129,920 | 313 incident CHD, 43 CHD deaths | 1981 to 1985 until 1999 | 15 to 19 | Median= 23 [Median= 38.5] | Incident CHD= 2.0, CHD death= 1.7 (CHD death); RRs higher with pregnancy complications | Reference group: Non-hypertensive pregnancy with term delivery & within highest four birth weight fifths; RR adjusted for perinatal factors except smoking |
| Heida | Netherlands; 2015 | Parous women who attended health checks in two cohort studies | History of hypertension during pregnancy | Response to study baseline questionnaire | 22,265 | 1478 incident CHD | From 1993 to 1997 until 1 January 2008 | Median=13 | 53.7 [29 at first pregnancy] [≤68] | 1.28 (1.16 if adjusted for baseline blood pressure) | Excludes type 2 diabetes, hypertension or cardiovascular disease prior to age of first pregnancy |
| Zhao | China; 2012 | Mothers with no prior CVD & attended a health check who previously delivered at a hospital (undefined catchment area) | Pregnancy-induced hypertension | Retrospective review of hospital records | 4630 | 29 incident MI | 2006 to 2007 until 2010 (but index pregnancies from 1976 to 2008) | From 2 to 34 years from index pregnancy | 27.4 at index pregnancy; 42 (exposed group) & 38 (unexposed group) at baseline [likely <50] | 3.91 | Reference group: No history of hypertensive pregnancy; RR adjusted for age at perinatal and other factors including blood pressure, lipids & body mass index measured at health exam |
| Hannaford | UK; 1997 | Non-users of pill in the RCGP Oral Contraception Study | History of toxaemia of pregnancy | Study forms and clinic records filled in by general practitioners | 23,000 | 285 incident CHD | 1968 to 1969 until 1995 | Up to 26 (214,356 women-years) | 29 [Possibly in their 40s] | 1.65; subsequent hypertension after baseline: No= NS, Yes= 1.59 | Never-users of oral contraceptive pill; RR adjusted for age, smoking, social class |

RR – relative risk; AOG – age of gestation; CHD – coronary heart disease; CVD – cardiovascular disease; MI – myocardial infarction; NS – not significant; Follow-up for outcomes usually inclusive of study time period except Wikstrom 2005; Incident CHD usually refers to first CHD hospitalisation or death except Ray 2005 (hospitalisations and/or revascularisations only) and Bhattacharya 2012 (hospitalisations only); *Information obtained by personal communication (Skjærven 2014 and Heida 2015).
Table C. Prospective studies investigating the relation between hypertension during pregnancy and cerebrovascular disease risk.

| Author (Country); Year | Study population | Type of exposure | Source of exposure data | No. of participants | No. of events | Year of study entry & exit | Follow-up duration from index pregnancy or study (years) | Mean age (years) at baseline [at outcome] | Relative risk | Comments |
|------------------------|------------------|------------------|-------------------------|--------------------|--------------|--------------------------|---------------------------------------------------------|----------------------------------------|-------------|----------|
| Männistö (Finland); 2013 | Mothers of offspring in a population-based birth cohort | Chronic & new-onset hypertension (e.g. isolated, gestational & pre-eclampsia) | Questionnaires at maternity clinic & linkage with antenatal records | 10,314 | 595 incident ischaemic stroke | 1966 until 2006 | Mean = 39.4 | ≈26 [66.7] | NS except gestational hypertension (1.59 and chronic hypertension (1.80) | Reference group: normotensive pregnancies; RR adjusted for perinatal factors |
| Skjærven (Norway); 2012 | Mothers with deliveries recorded in a national birth registry | Pre-eclampsia | Retrospective review of birth registry | 836,147 | 1119 CeVD deaths | 1967 to 2002 until 2009 | Median = 25 | 24.3 [49.1*] | One lifetime pregnancy: 2.1 to 10.4 with higher RR for preterm births; NS for pre-eclampsia involving ≥2 lifetime pregnancies | Reference group: ≥2 lifetime pregnancies & no pre-eclampsia; RR adjusted for perinatal & reproductive factors |
| Bhattacharya (Scotland); 2012 | Mothers with deliveries recorded in population-based birth registry | Gestational hypertension & pre-eclampsia (including eclampsia) | Retrospective review of maternity and birth registers | 34,854 | 266 CeVD deaths; 1459 incident CeVD | From 1950 to 2008 | Up to 58 years (mean =40) | ≈24 [=64 at death] | NS for pre-eclampsia; for gestational hypertension, NS for incident CeVD, 1.28 for CeVD death | Hospitalisations not modelled as incident outcomes; Risk estimates are odds ratios |
| Lykke (Denmark); 2009 | Mothers with deliveries recorded in a national birth registry | Gestational hypertension & pre-eclampsia | Retrospective review of birth registry | 782,287 | 8987 incident CeVD | 1978 to 2007 until 2008 | Mean = 14.6 | 26.8 [41.6] | From 1.43 to 1.58; higher RR with pregnancy complications & repeated pre-eclampsia | Reference group: no hypertensive pregnancy; RR adjusted for perinatal factors (but not for body size or smoking during pregnancy) |
| Arnadottir (Iceland); 2005 | Mothers with deliveries recorded in a single hospital (undefined catchment area) | Chronic hypertension, gestational hypertension, pre-eclampsia & eclampsia | Retrospective review of maternity records | 325 exposed, 629 unexposed | 72 CeVD deaths | 1931 to 1947 until 1996 | Median = 50 (exposed group), 55 (unexposed group) | Either ages not mentioned | NS overall, but 8.4 for aged ≤64 years (NS for older ages) | Exposed matched for date of delivery, parity, and age at pregnancy; RR unadjusted for other covariates |
| Ray (Canada); 2005 | Nulliparous mothers with deliveries recorded in province-wide health insurance database | Maternal placental syndrome | Retrospective review of health insurance database | 1,026,265 | 415 incident CeVD | From 1990 to 2004 | Median = 8.7 | 28 [38.3] | 2.0 (1.7 to 2.3) | Reference group: No maternal placental syndrome; RR adjusted for perinatal factors and medical history including gestational diabetes, & history of hypertension or dyslipidaemia |
| Study baseline period: Outside of index pregnancy | Wilson (Scotland); 2003 | Mothers with deliveries recorded in population-based birth registry, & traced for assessment for this study | Gestational hypertension & pre-eclampsia | Retrospective review of maternity and birth registers | 3593 | 69 incident CeVD, 34 CeVD deaths | 1951 to 1970 for events occurring between 1980 & 1999 | Not mentioned | 24 [possibly between 53 and 68] | Gestational hypertension: NS for both outcomes; Pre-eclampsia or eclampsia: from 2.10 (incident CeVD) to 3.59 (CeVD deaths) | No prior hypertension during index pregnancy; Reference group: No hypertension during pregnancy; Exposed group matched by age at delivery & birth year to unexposed group; RR adjusted for some perinatal factors |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Heida (Netherlands); 2015 | Parous women who attended health checks in two cohort studies | History of hypertension during pregnancy | Response to study baseline questionnaire | 22,265 | 720 incident stroke | From 1993 to 1997 until 1 January 2008 | Median=13 | 53.7 [29 at first pregnancy] [≥68] | 1.26 (NS if adjusted for baseline blood pressure) | Excludes type 2 diabetes, hypertension or cardiovascular disease prior to age of first pregnancy; ischaemic not differentiated from haemorrhagic subtype |
| Hannaford (UK); 1997 | Non-users of pill in the RCGP Oral Contraception Study | History of toxaemia of pregnancy | Study forms and clinic records filled in by general practitioners | 23,000 | 118 incident CeVD | 1968 to 1969 until 1995 | Up to 26 (214,356 women-years) | 29 [Possibly in their 40s] | NS (overall and when stratified by subsequent hypertension after baseline) | Never-users of oral contraceptive pill; RR adjusted for age, smoking, social class |

RR – relative risk; AOG – age of gestation; CeVD – cerebrovascular disease; CVD – cardiovascular disease; MI – myocardial infarction; NS – not significant; Follow-up for outcomes usually inclusive of study time period; Incident CeVD usually refers to first CeVD hospitalisation or death except Ray 2005 (hospitalisations and/or revascularisations only); *Information obtained by personal communication (Skjærven 2014 and Heida 2015).
Figure A. Estimated women’s ages (mean or median) at the beginning and end of follow-up of prospective studies investigating the relation between hypertension during pregnancy and coronary heart disease risk. Numbers on bars are numbers of disease events. Studies in dotted lines are those with follow-up up to around middle age.
Figure B. Estimated women’s ages (mean or median) at the beginning and end of follow-up of prospective studies investigating the relation between hypertension during pregnancy and cerebrovascular disease risk. Numbers on bars are numbers of disease events. Studies in dotted lines are those with follow-up up to around middle age.
References

Arnadottir GA, Geirsson RT, Arngrimsson R, Jonsdottir LS, Olafsson O. Cardiovascular death in women who had hypertension in pregnancy: a case-control study. BJOG 2005;112:286-92.

Bhattacharya S, Prescott GJ, Iversen L, Campbell DM, Smith WC, Hannaford PC. Hypertensive disorders of pregnancy and future health and mortality: A record linkage study. Pregnancy Hypertens 2012;2:1-7.

Hannaford P, Ferry S, Hirsch S. Cardiovascular sequelae of toxaemia of pregnancy. Heart 1997;77:154-8.

Heida KY, Franx A, Van Rijn BB, Eijkemans MJ, Boer JM, Verschuren MW, Oudijk MA, Bots ML, Van Der Schouw YT. Earlier age of onset of chronic hypertension and Type 2 diabetes mellitus after a hypertensive disorder of pregnancy or gestational diabetes mellitus. Hypertension 2015;66:1116-22.

Lykke JA, Langhoff-Roos J, Sibai BM, Funai EF, Triche EW, Paidas MJ. Hypertensive pregnancy disorders and subsequent cardiovascular morbidity and type 2 diabetes mellitus in the mother. Hypertension 2009;53:944-51.

Männisto T, Mendola P, Vaarasmaki M, Jarvelin MR, Hartikainen AL, Pouta A, Suvanto E. Elevated blood pressure in pregnancy and subsequent chronic disease risk. Circulation 2013;127:681-90.

Ray JG, Vermeulen MJ, Schull MJ, Redelmeier DA. Cardiovascular health after maternal placental syndromes (CHAMPS): population-based retrospective cohort study. Lancet 2005;366:1797-803.

Skjaerven R, Wilcox AJ, Klungsoyr K, Irgens LM, Vikse BE, Vatten LJ, Lie RT. Cardiovascular mortality after pre-eclampsia in one child mothers: prospective, population based cohort study. BMJ 2012;345:e7677.

Smith GC, Pell JP, Walsh D. Pregnancy complications and maternal risk of ischaemic heart disease: a retrospective cohort study of 129,290 births. Lancet 2001;357:2002-6.

Wikstrom AK, Haglund B, Olovsson M, Lindeberg SN. The risk of maternal ischaemic heart disease after gestational hypertensive disease. BJOG 2005;112:1486-91.

Wilson BJ, Watson MS, Prescott GJ, Sunderland S, Campbell DM, Hannaford P, Smith WC. Hypertensive diseases of pregnancy and risk of hypertension and stroke in later life: results from cohort study. BMJ 2003;326:845.

Zhao HY, Chen XW, Niu JQ, Hou GS, Sun J, Jin C, Gao JS, Zheng XM, Wu SL. [History of pregnancy induced hypertension is linked with increased risk of cardio-cerebral vascular events]. Zhonghua Xin Xue Guan Bing Za Zhi 2012;40:645-51.